Suppr超能文献

SHP2促进HER2诱导的信号传导和转化的分子机制。

Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.

作者信息

Zhou Xiangdong, Agazie Yehenew M

机构信息

Department of Biochemistry and The Marry Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia 26506, USA.

出版信息

J Biol Chem. 2009 May 1;284(18):12226-34. doi: 10.1074/jbc.M900020200. Epub 2009 Mar 4.

Abstract

The Src homology phosphotyrosyl phosphatase 2 (SHP2) plays a positive role in HER2-induced signaling and transformation, but its mechanism of action is poorly understood. Given the significance of HER2 in breast cancer, defining a mechanism for SHP2 in the HER2 signaling pathway is of paramount importance. In the current report we show that SHP2 positively modulates the Ras-extracellular signal-regulated kinase 1 and 2 and the phospoinositide-3-kinase-Akt pathways downstream of HER2 by increasing the half-life the activated form of Ras. This is accomplished by dephosphorylating an autophosphorylation site on HER2 that serves as a docking platform for the SH2 domains of the Ras GTPase-activating protein (RasGAP). The net effect is an increase in the intensity and duration of GTP-Ras levels with the overall impact of enhanced HER2 signaling and cell transformation. In conformity to these findings, the HER2 mutant that lacks the SHP2 target site exhibits an enhanced signaling and cell transformation potential. Therefore, SHP2 promotes HER2-induced signaling and transformation at least in part by dephosphorylating a negative regulatory autophosphorylation site. These results suggest that SHP2 might serve as a therapeutic target against breast cancer and other cancers characterized by HER2 overexpression.

摘要

Src同源磷酸酪氨酸磷酸酶2(SHP2)在HER2诱导的信号传导和细胞转化中发挥积极作用,但其作用机制尚不清楚。鉴于HER2在乳腺癌中的重要性,明确SHP2在HER2信号通路中的作用机制至关重要。在本报告中,我们表明SHP2通过延长Ras激活形式的半衰期,正向调节HER2下游的Ras-细胞外信号调节激酶1和2以及磷酸肌醇-3-激酶-Akt信号通路。这是通过使HER2上的一个自磷酸化位点去磷酸化来实现的,该位点作为Ras GTP酶激活蛋白(RasGAP)的SH2结构域的对接平台。最终结果是GTP-Ras水平的强度和持续时间增加,对HER2信号传导增强和细胞转化产生总体影响。与这些发现一致,缺乏SHP2靶位点的HER2突变体表现出增强的信号传导和细胞转化潜力。因此,SHP2至少部分通过使负性调节自磷酸化位点去磷酸化来促进HER2诱导的信号传导和细胞转化。这些结果表明,SHP2可能作为针对乳腺癌和其他以HER2过表达为特征的癌症的治疗靶点。

相似文献

1
Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
J Biol Chem. 2009 May 1;284(18):12226-34. doi: 10.1074/jbc.M900020200. Epub 2009 Mar 4.
3
Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Cell Death Differ. 2008 Jun;15(6):988-96. doi: 10.1038/cdd.2008.54. Epub 2008 Apr 18.
6
A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation.
J Biol Chem. 2005 Feb 18;280(7):5350-60. doi: 10.1074/jbc.M410012200. Epub 2004 Dec 1.
7
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.
Mol Cell Biol. 2003 Nov;23(21):7875-86. doi: 10.1128/MCB.23.21.7875-7886.2003.
9
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
J Biol Chem. 2013 Jun 7;288(23):16895-16904. doi: 10.1074/jbc.M112.434217. Epub 2013 Apr 23.
10
SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
Histopathology. 2008 Oct;53(4):389-402. doi: 10.1111/j.1365-2559.2008.03103.x. Epub 2008 Jul 15.

引用本文的文献

1
Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes.
ACS Bio Med Chem Au. 2023 Jul 14;3(5):418-428. doi: 10.1021/acsbiomedchemau.3c00024. eCollection 2023 Oct 18.
2
-Derived Extracellular Vesicles Provide Antioxidant Protection in Ulcerative Colitis.
Molecules. 2023 Aug 22;28(17):6182. doi: 10.3390/molecules28176182.
4
Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.
RSC Med Chem. 2022 Jan 15;13(3):246-257. doi: 10.1039/d1md00386k. eCollection 2022 Mar 23.
5
Strategies to overcome drug resistance using SHP2 inhibitors.
Acta Pharm Sin B. 2021 Dec;11(12):3908-3924. doi: 10.1016/j.apsb.2021.03.037. Epub 2021 Mar 28.
6
SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
Mol Cancer Res. 2021 Nov;19(11):1946-1956. doi: 10.1158/1541-7786.MCR-21-0060. Epub 2021 Aug 13.
8
Cutting the Brakes on Ras-Cytoplasmic GAPs as Targets of Inactivation in Cancer.
Cancers (Basel). 2020 Oct 21;12(10):3066. doi: 10.3390/cancers12103066.
9
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.
ACS Omega. 2020 Sep 25;5(39):25113-25124. doi: 10.1021/acsomega.0c02746. eCollection 2020 Oct 6.
10
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Cancer Res. 2020 Nov 1;80(21):4840-4853. doi: 10.1158/0008-5472.CAN-20-1634. Epub 2020 Sep 14.

本文引用的文献

1
Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Cell Death Differ. 2008 Jun;15(6):988-96. doi: 10.1038/cdd.2008.54. Epub 2008 Apr 18.
3
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration.
Mol Syst Biol. 2006;2:54. doi: 10.1038/msb4100094. Epub 2006 Oct 3.
4
The ErbB2 signaling network as a target for breast cancer therapy.
J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):13-25. doi: 10.1007/s10911-006-9009-1.
6
Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant.
Biochim Biophys Acta. 2006 Jan;1763(1):45-56. doi: 10.1016/j.bbamcr.2005.11.013. Epub 2005 Dec 20.
7
A role for the scaffolding adapter GAB2 in breast cancer.
Nat Med. 2006 Jan;12(1):114-21. doi: 10.1038/nm1341. Epub 2005 Dec 20.
8
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
Br J Haematol. 2005 May;129(3):333-9. doi: 10.1111/j.1365-2141.2005.05457.x.
9
Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.
J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):297-310. doi: 10.1007/s10911-004-1402-z.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验